Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.81 |
| ▸ | CDK4 | P11802 | 17/20 | 0.81 |
| ▸ | CCND1 | P24385 | 17/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.81 |
| ▸ | CCND3 | P30281 | 3/20 | 0.80 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.80 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.80 |
| ▸ | CDK9 | P50750 | 2/20 | 0.80 |
| ▸ | TTK | P33981 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | CCNH | P51946 | 1/20 | 0.67 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.67 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.67 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980288 | 1.00 | CDK2 (0.81) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959471 | 1.00 | CDK2 (0.81) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL4549924 | 0.90 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29356370 | 0.89 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL10082028 | 0.89 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29763763 | 0.89 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29514690 | 0.88 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29375833 | 0.88 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959535 | 0.87 | CDK2 (0.86) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959293 | 0.84 | CDK2 (0.57) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | CDK2 35/4885CDK4 52/4885CCND1 71/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | CDK2 35/4885CDK4 52/4885CCND1 71/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | CDK2 17/4885CDK4 11/4885CCND1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.